Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Everest Organics Ltd Fundamentals

Market Cap
₹ 103.24 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
2.25
Debt to Equity
0.97
ROE
-0.17
EPS (TTM)
0.24
Dividend Yield
0.00 %
Book Value
57.47

Click here to know more about Fundamentals

Everest Organics Ltd Financials

Everest Organics Ltd Financials

Everest Organics Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 74.15 % 74.15 % 74.15 % 74.15 %
Retail 20.00 % 19.99 % 19.60 % 19.41 %
Others 5.85 % 5.86 % 6.25 % 6.44 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

74.15%

Retail

20.00%

Others

5.85%

Mutual Funds

0.00%

FII

0.00%

Promoters

74.15%

Retail

19.99%

Others

5.86%

Mutual Funds

0.00%

FII

0.00%

Promoters

74.15%

Retail

19.60%

Others

6.25%

Mutual Funds

0.00%

FII

0.00%

Promoters

74.15%

Retail

19.41%

Others

6.44%

Mutual Funds

0.00%

FII

0.00%

Resistance and Support

₹130.07

PIVOT

resistance-arrow
Resistance
First Resistance₹131.983
Second Resistance₹134.917
Third Resistance₹136.833
support-arrow
Support
First Support₹127.133
Second Support₹125.217
Third Support₹122.283

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day6,5714,31765.70
Week1,6813,6510.00
1 Month1,6812,6410.00
6 Months697,184459,92267.66

About Everest Organics Ltd

Everest Organics Ltd was incorporated at Hyderabad in Feb.'93. It was promoted by S K Srihari Raju and S K Chittiramabhadra Raju. The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediaries. The Company commenced its commercial operations in the year 1993. It set up a plant at Aroor, Andhra Pradesh to manufacture bulk drugs and formulations. It came out with a public issue in Jan.'95 to part-finance the project. Commercial production of ciprofloxacin and omerprazole commenced in Feb.'96. The company preferred to manufacture para hydroxy phynyl glycin (PHPG), but due to market conditions, it decided to drop manufacturing of PHPG and has decided to enhance the capacity of ciprofloxacin from 30 tpa to 120 tpa and also to manufacture enrofloxacin/naproxen. The company increased its installed capacity of Benzimidazole by 60 tpa there by taking its capacity to 120 tpa. The installed capacity of Omeprazole Op Sulphide was increased from 15 TPA to 30 TPA. It introduced one more new product by name Esomeprazole Magnesium by creating additional facility by making investment in plant & machinery in 2007-08.

Managing Director

1993

Founded

Srikakarlapudi Sirisha

NSE Symbol

NA

Everest Organics Ltd Management

NameDesignation
S K Hari KrishnaWhole-time Director
A ParvatisemDirector (Technical)
K. Ramakrishnam RajuChairman & Independent Directo
Raju S KakarlapudiNon Executive Director
Srikakarlapudi SirishaManaging Director & CEO
Venkatasatyanarayana Murthy ChayalyIndependent Director
Abdur RahmanCompany Sec. & Compli. Officer
SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPUIndependent Director

Everest Organics Ltd News

Everest Organics to hold board meeting
On 27 May 2024
Everest Organics standalone net profit declines 98.68% in the December 2023 quarter
Sales rise 21.30% to Rs 52.51 crore
Everest Organics to declare Quarterly Result
On 9 February 2024
Everest Organics standalone net profit declines 96.81% in the September 2023 quarter
Sales rise 7.57% to Rs 49.45 crore
Everest Organics to conduct board meeting
On 11 November 2023
Everest Organics to convene AGM
On 25 September 2023
Everest Organics reports standalone net profit of Rs 0.03 crore in the June 2023 quarter
Sales decline 0.84% to Rs 42.67 crore
Everest Organics to announce Quarterly Result
On 12 August 2023
Everest Organics standalone net profit declines 62.07% in the March 2023 quarter
Sales decline 7.89% to Rs 50.75 crore
Everest Organics to hold board meeting
On 27 May 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 358724.57 Cr
₹ 1,495.10
(-2.87 %)
87.07
Cipla Ltd₹ 120233.22 Cr
₹ 1,489.15
(0.46 %)
32.36
Zydus Lifesciences Ltd₹ 109282.04 Cr
₹ 1,086.05
(0.50 %)
31.67
Divis Laboratories Ltd₹ 109187.23 Cr
₹ 4,113.00
(1.34 %)
80.00
Dr Reddys Laboratories Ltd₹ 98384.41 Cr
₹ 5,897.70
(0.42 %)
22.64

Everest Organics Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Everest Organics Ltd shares in BlinkX

Everest Organics Ltd's P/E ratio is 0.00 times as of May 23, 2024 at 04:00 PM.

Everest Organics Ltd's most recent financial reports indicate a price-to-book ratio of 2.25, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Everest Organics Ltd's market is 103 Cr as on May 23, 2024 at 04:00 PM.

The current financial records of Everest Organics Ltd show a -0.17% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Everest Organics Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Everest Organics Ltd stands at 74.15%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.